Schering-Plough Merger Offers Merck OTC Business, Zegerid Switch Rights
Merck stands to pick up the switch rights to the proton pump inhibitor Zegerid at the head of a strong switch program if its planned acquisition of Schering-Plough succeeds
Merck stands to pick up the switch rights to the proton pump inhibitor Zegerid at the head of a strong switch program if its planned acquisition of Schering-Plough succeeds